If you're worried about having enough passive income to maintain your lifestyle during retirement, you're not alone. Having to spend more just to maintain their current standard of living is a cons...

Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer are included in this Analyst Blog.

In the latest trading session, AbbVie (ABBV) closed at $180, marking a +0.9% move from the previous day.

AbbVie (ABBV 2.37%) and Amgen (AMGN 0.84%) have a lot in common. They are both leading drugmakers and have strong dividend track records.

Stock market investors have plenty of reasons to celebrate as 2024 comes to a close. The S&P 500 index set multiple new record highs during the year, delivering a spectacular 25% return year to dat...

Santa Claus will soon be on his way delivering presents to kids around the world. But could the jolly gift-giver bring something for investors, too?

What will be the hottest investing trend on Wall Street next year? Maybe artificial intelligence will keep up its momentum, or perhaps interest in weight loss-focused pharmaceutical companies will ...

Gilead, Eli Lilly, Vertex Pharmaceuticals and AbbVie have outperformed the industry this year and are likely to see continued momentum in 2025.

In the most recent trading session, AbbVie (ABBV) closed at $171.63, indicating a -1% shift from the previous trading day.

AbbVie Inc is a global biopharmaceutical company that specializes in the discovery, development, manufacturing, and marketing of advanced medicines. AbbVie focuses primarily on immunology, oncology...

Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.

AbbVie is set to acquire privately held biotech, Nimble Therapeutics, for $200 million to strengthen its immunology pipeline.

Proposed acquisition adds Nimble's lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for psoriasis, and a pipeline of other novel oral peptide assets across aut...

AbbVie Inc. has rebounded from setbacks with a strong pipeline, including the promising Parkinson's drug Tavapadon, which shows blockbuster potential. Key growth drivers like SKYRIZI and RINVOQ are...

Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease, ALIA-1758, and novel blood-brain barrier (BBB)-crossing technology to strengthen neuroscience pipeline an...